secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001140361-26-012158
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming
--------------------------------------------------------------------------------

- Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.
- Cash $17.7M plus $10M credit line from chairman; runway through April 2027.
- Belapectin NAVIGATE trial: varices incidence reduced 49.3% in per-protocol (p=0.04); U.S. subgroup 68.1% (p=0.02).
- Additional biomarker data (FibroScan, ELF, PRO-C3) support antifibrotic activity; oral/poster presentations at EASL 2026.
- Upcoming FDA meeting in Q2 2026 to align on next steps; no approved therapy for MASH cirrhosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/0001140361-26-012158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/ef20068722_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-012158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer